{"count": 9, "results": [{"_id": "32073735", "pmid": 32073735, "pmcid": "PMC7171409", "title": "Hyperlipidemia inhibits the protective effect of lisinopril after myocardial infarction via activation of dendritic cells", "journal": "J Cell Mol Med", "authors": ["Ma Y", "Ma L", "Ma J", "Wu R", "Zou Y", "Ge J"], "date": "2020-04-01T00:00:00Z", "doi": "10.1111/jcmm.15060", "meta_date_publication": "2020 Apr", "meta_volume": "24", "meta_issue": "7", "meta_pages": "4082-4091", "score": 50256.34, "text_hl": "Hence, @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ can reduce the infiltration of @GENE_ITGAX @GENE_16411 @@@CD11c@@@+@GENE_PTPRC @GENE_19264 @@@CD45@@@+DCs into @<m>DISEASE_Cardiomyopathies</m> @DISEASE_MESH:D009202 @@@myocardial@@@ tissue by inhibiting the release of spleen-derived DCs after @DISEASE_Myocardial_Infarction @DISEASE_MESH:D009203 @@@MI@@@. ", "citations": {"NLM": "Ma Y, Ma L, Ma J, Wu R, Zou Y, Ge J. Hyperlipidemia inhibits the protective effect of lisinopril after myocardial infarction via activation of dendritic cells J Cell Mol Med. 2020 Apr;24(7):4082-4091. PMID: 32073735", "BibTeX": "@article{32073735, title={Hyperlipidemia inhibits the protective effect of lisinopril after myocardial infarction via activation of dendritic cells}, author={Ma Y and Ma L and Ma J and Wu R and Zou Y and Ge J}, journal={J Cell Mol Med}, volume={24}, number={7}, pages={4082-4091}}"}}, {"_id": "20051877", "pmid": 20051877, "title": "How to protect doxorubicin-induced cardiomyopathy in male albino rats?", "journal": "J Cardiovasc Pharmacol", "authors": ["Shaker O", "Sourour DA"], "date": "2010-03-01T00:00:00Z", "doi": "10.1097/FJC.0b013e3181cf91ac", "meta_date_publication": "2010 Mar", "meta_volume": "55", "meta_issue": "3", "meta_pages": "262-8", "score": 50072.008, "text_hl": "The present study was designed to compare the cardioprotective effects of the combination of @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ with @GENE_GNRHR @GENE_81668 @@@growth hormone@@@ over @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ alone in @CHEMICAL_Doxorubicin @CHEMICAL_MESH:D004317 @@@doxorubicin@@@ (@CHEMICAL_Doxorubicin @CHEMICAL_MESH:D004317 @@@Dox@@@)-induced @<m>DISEASE_Cardiomyopathies</m> @DISEASE_MESH:D009202 @@@cardiomyopathy@@@ in @SPECIES_10116 @@@rats@@@. ", "citations": {"NLM": "Shaker O, Sourour DA. How to protect doxorubicin-induced cardiomyopathy in male albino rats? J Cardiovasc Pharmacol. 2010 Mar;55(3):262-8. PMID: 20051877", "BibTeX": "@article{20051877, title={How to protect doxorubicin-induced cardiomyopathy in male albino rats?}, author={Shaker O and Sourour DA}, journal={J Cardiovasc Pharmacol}, volume={55}, number={3}, pages={262-8}}"}}, {"_id": "29971804", "pmid": 29971804, "title": "An evidence-based systematic review of the off-label uses of lisinopril.", "journal": "Br J Clin Pharmacol", "authors": ["Sadat-Ebrahimi SR", "Parnianfard N", "Vahed N", "Babaei H", "Ghojazadeh M", "Tang S", "Azarpazhooh A"], "date": "2018-11-01T00:00:00Z", "doi": "10.1111/bcp.13705", "meta_date_publication": "2018 Nov", "meta_volume": "84", "meta_issue": "11", "meta_pages": "2502-2521", "score": 50068.418, "text_hl": "An evidence-based systematic review of the off-label uses of @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@.", "citations": {"NLM": "Sadat-Ebrahimi SR, Parnianfard N, Vahed N, Babaei H, Ghojazadeh M, Tang S, Azarpazhooh A. An evidence-based systematic review of the off-label uses of lisinopril. Br J Clin Pharmacol. 2018 Nov;84(11):2502-2521. PMID: 29971804", "BibTeX": "@article{29971804, title={An evidence-based systematic review of the off-label uses of lisinopril.}, author={Sadat-Ebrahimi SR and Parnianfard N and Vahed N and Babaei H and Ghojazadeh M and Tang S and Azarpazhooh A}, journal={Br J Clin Pharmacol}, volume={84}, number={11}, pages={2502-2521}}"}}, {"_id": "24459612", "pmid": 24459612, "pmcid": "PMC3871420", "title": "A Randomized, Double-Blind Trial of Lisinopril and Losartan for the Treatment of Cardiomyopathy in Duchenne Muscular Dystrophy", "journal": "PLoS Curr", "authors": ["Allen HD", "Flanigan KM", "Thrush PT", "Dvorchik I", "Yin H", "Canter C", "Connolly AM", "Parrish M", "McDonald CM", "Braunlin E", "Colan SD", "Day J", "Darras B", "Mendell JR"], "date": "2013-12-12T00:00:00Z", "doi": "10.1371/currents.md.2cc69a1dae4be7dfe2bcb420024ea865", "meta_date_publication": "2013 Dec 12", "meta_volume": "5", "meta_issue": "", "meta_pages": "", "score": 50067.637, "text_hl": "A Randomized, Double-Blind Trial of @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@Lisinopril@@@ and @CHEMICAL_Losartan @CHEMICAL_MESH:D019808 @@@Losartan@@@ for the Treatment of @<m>DISEASE_Cardiomyopathies</m> @DISEASE_MESH:D009202 @@@Cardiomyopathy@@@ in @DISEASE_Muscular_Dystrophy_Duchenne @DISEASE_MESH:D020388 @@@Duchenne Muscular Dystrophy@@@", "citations": {"NLM": "Allen HD, Flanigan KM, Thrush PT, Dvorchik I, Yin H, Canter C, Connolly AM, Parrish M, McDonald CM, Braunlin E, Colan SD, Day J, Darras B, Mendell JR. A Randomized, Double-Blind Trial of Lisinopril and Losartan for the Treatment of Cardiomyopathy in Duchenne Muscular Dystrophy PLoS Curr. 2013 Dec 12;5():. PMID: 24459612", "BibTeX": "@article{24459612, title={A Randomized, Double-Blind Trial of Lisinopril and Losartan for the Treatment of Cardiomyopathy in Duchenne Muscular Dystrophy}, author={Allen HD and Flanigan KM and Thrush PT and Dvorchik I and Yin H and Canter C and Connolly AM and Parrish M and McDonald CM and Braunlin E and Colan SD and Day J and Darras B and Mendell JR}, journal={PLoS Curr}, volume={5}}"}}, {"_id": "25821645", "pmid": 25821645, "pmcid": "PMC4358986", "title": "Correction: A Randomized, Double-Blind Trial of Lisinopril and Losartan for the Treatment of Cardiomyopathy in Duchenne Muscular Dystrophy", "journal": "PLoS Curr", "authors": ["PLOS Currents"], "date": "2015-03-06T00:00:00Z", "doi": "10.1371/currents.md.995441cf82fd58a29c6e4fdd5cd36b89", "meta_date_publication": "2015 Mar 6", "meta_volume": "7", "meta_issue": "", "meta_pages": "", "score": 50065.207, "text_hl": "Correction: A Randomized, Double-Blind Trial of @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@Lisinopril@@@ and @CHEMICAL_Losartan @CHEMICAL_MESH:D019808 @@@Losartan@@@ for the Treatment of @<m>DISEASE_Cardiomyopathies</m> @DISEASE_MESH:D009202 @@@Cardiomyopathy@@@ in @DISEASE_Muscular_Dystrophy_Duchenne @DISEASE_MESH:D020388 @@@Duchenne Muscular Dystrophy@@@", "citations": {"NLM": "PLOS Currents. Correction: A Randomized, Double-Blind Trial of Lisinopril and Losartan for the Treatment of Cardiomyopathy in Duchenne Muscular Dystrophy PLoS Curr. 2015 Mar 6;7():. PMID: 25821645", "BibTeX": "@article{25821645, title={Correction: A Randomized, Double-Blind Trial of Lisinopril and Losartan for the Treatment of Cardiomyopathy in Duchenne Muscular Dystrophy}, author={PLOS Currents}, journal={PLoS Curr}, volume={7}}"}}, {"_id": "28290816", "pmid": 28290816, "title": "[Effects of Amlodipine/Lisinopril Fixed-Dose Combination on Severity of Left Ventricular Hypertrophy and Parameters of Myocardial Stiffness in Patients With Hypertension].", "journal": "Kardiologiia", "authors": ["Ostroumova OD", "Kochetkov AI"], "date": "2016-12-01T00:00:00Z", "doi": "10.18565/cardio.2016.11.27-37", "meta_date_publication": "2016 Dec", "meta_volume": "56", "meta_issue": "11", "meta_pages": "27-37", "score": 50057.027, "text_hl": "[Effects of @CHEMICAL_Amlodipine @CHEMICAL_MESH:D017311 @@@Amlodipine@@@/@<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@Lisinopril@@@ Fixed-Dose Combination on Severity of @DISEASE_Hypertrophy_Left_Ventricular @DISEASE_MESH:D017379 @@@Left Ventricular Hypertrophy@@@ and Parameters of @<m>DISEASE_Cardiomyopathies</m> @DISEASE_MESH:D009202 @@@Myocardial@@@ Stiffness in @SPECIES_9606 @@@Patients@@@ With @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@Hypertension@@@].", "citations": {"NLM": "Ostroumova OD, Kochetkov AI. [Effects of Amlodipine/Lisinopril Fixed-Dose Combination on Severity of Left Ventricular Hypertrophy and Parameters of Myocardial Stiffness in Patients With Hypertension]. Kardiologiia. 2016 Dec;56(11):27-37. PMID: 28290816", "BibTeX": "@article{28290816, title={[Effects of Amlodipine/Lisinopril Fixed-Dose Combination on Severity of Left Ventricular Hypertrophy and Parameters of Myocardial Stiffness in Patients With Hypertension].}, author={Ostroumova OD and Kochetkov AI}, journal={Kardiologiia}, volume={56}, number={11}, pages={27-37}}"}}, {"_id": "9573498", "pmid": 9573498, "title": "Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. The Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial Investigators.", "journal": "J Card Fail", "authors": ["Massie BM", "Cleland JG", "Armstrong PW", "Horowitz JD", "Packer M", "Poole-Wilson PA", "Ryden L"], "date": "1998-03-01T00:00:00Z", "doi": "10.1016/s1071-9164(98)90502-4", "meta_date_publication": "1998 Mar", "meta_volume": "4", "meta_issue": "1", "meta_pages": "3-8", "score": 50051.652, "text_hl": "The Assessment of Treatment with @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@Lisinopril@@@ and Survival (ATLAS) Trial Investigators.", "citations": {"NLM": "Massie BM, Cleland JG, Armstrong PW, Horowitz JD, Packer M, Poole-Wilson PA, Ryden L. Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. The Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial Investigators. J Card Fail. 1998 Mar;4(1):3-8. PMID: 9573498", "BibTeX": "@article{9573498, title={Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. The Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial Investigators.}, author={Massie BM and Cleland JG and Armstrong PW and Horowitz JD and Packer M and Poole-Wilson PA and Ryden L}, journal={J Card Fail}, volume={4}, number={1}, pages={3-8}}"}}, {"_id": "30131930", "pmid": 30131930, "pmcid": "PMC6101465", "title": "Thyrotoxic Periodic Paralysis and Cardiomyopathy in a Patient with Graves' Disease", "journal": "Cureus", "authors": ["Abbasi AA", "Chandar P", "Shankar S", "Gupta SS", "Kupfer Y"], "date": "2018-06-19T00:00:00Z", "doi": "10.7759/cureus.2837", "meta_date_publication": "2018 Jun 19", "meta_volume": "10", "meta_issue": "6", "meta_pages": "e2837", "score": 50045.055, "text_hl": "Emergent management is essential as @DISEASE_188580 @DISEASE_OMIM:188580 @@@TPP@@@ and cardiac events secondary to @<m>DISEASE_Cardiomyopathies</m> @DISEASE_MESH:D009202 @@@thyrotoxic cardiomyopathy@@@ can be fatal. ", "citations": {"NLM": "Abbasi AA, Chandar P, Shankar S, Gupta SS, Kupfer Y. Thyrotoxic Periodic Paralysis and Cardiomyopathy in a Patient with Graves' Disease Cureus. 2018 Jun 19;10(6):e2837. PMID: 30131930", "BibTeX": "@article{30131930, title={Thyrotoxic Periodic Paralysis and Cardiomyopathy in a Patient with Graves' Disease}, author={Abbasi AA and Chandar P and Shankar S and Gupta SS and Kupfer Y}, journal={Cureus}, volume={10}, number={6}, pages={e2837}}"}}, {"_id": "30326162", "pmid": 30326162, "title": "Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy.", "journal": "Cochrane Database Syst Rev", "authors": ["Bourke JP", "Bueser T", "Quinlivan R"], "date": "2018-10-16T00:00:00Z", "doi": "10.1002/14651858.CD009068.pub3", "meta_date_publication": "2018 Oct 16", "meta_volume": "10", "meta_issue": "10", "meta_pages": "CD009068", "score": 50037.58, "text_hl": "Therefore, although there is some evidence from non-randomised data to support the prophylactic use of @CHEMICAL_Perindopril @CHEMICAL_MESH:D020913 @@@perindopril@@@ for cardioprotection ahead of detectable @<m>DISEASE_Cardiomyopathies</m> @DISEASE_MESH:D009202 @@@cardiomyopathy@@@, and for @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ or @CHEMICAL_Losartan @CHEMICAL_MESH:D019808 @@@losartan@@@ plus @CHEMICAL_Eplerenone @CHEMICAL_MESH:D000077545 @@@eplerenone@@@ once @<m>DISEASE_Cardiomyopathies</m> @DISEASE_MESH:D009202 @@@cardiomyopathy@@@ is detectable, this must be considered of very low certainty. ", "citations": {"NLM": "Bourke JP, Bueser T, Quinlivan R. Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy. Cochrane Database Syst Rev. 2018 Oct 16;10(10):CD009068. PMID: 30326162", "BibTeX": "@article{30326162, title={Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy.}, author={Bourke JP and Bueser T and Quinlivan R}, journal={Cochrane Database Syst Rev}, volume={10}, number={10}, pages={CD009068}}"}}]}